^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclophosphamide

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    1d
    BRIA-ABC: Combination Study of SV-BR-1-GM With Retifanlimab (clinicaltrials.gov)
    P1/2, N=36, Completed, BriaCell Therapeutics Corporation | Enrolling by invitation --> Completed | Trial completion date: Nov 2028 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    HER-2 positive • HER-2 negative • PGR positive
    |
    cyclophosphamide • Zynyz (retifanlimab-dlwr) • Bria-IMT (SV-BR-1-GM)
    1d
    Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • celecoxib oral
    1d
    Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P=N/A, N=80, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • cytarabine • cyclophosphamide • Blincyto (blinatumomab) • fludarabine IV
    3d
    Defying the odds: A rare case of primary breast double-hit lymphoma with remarkable remission. (PubMed, SAGE Open Med Case Rep)
    Primary breast double-hit lymphoma is a very rare, highly aggressive malignancy that presents a great challenge regarding proper diagnosis and optimal treatment. Our case involved high-grade B-cell lymphoma with MYC and BCL2 rearrangement (double hit), treated with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin chemotherapy, resulting in complete resolution.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone
    3d
    Unusual Ampullary Presentation of Pediatric Burkitt Lymphoma: Case Report and Literature Review. (PubMed, Clin Med Insights Case Rep)
    Given persistent cholestasis and bleeding risk, the patient underwent Roux-en-Y choledochojejunostomy for biliary decompression, followed by initiation of rituximab-cyclophosphamide-vincristine-doxorubicin-high-dose methotrexate/rituximab-ifosfamide-etoposide-high-dose cytarabine (R-CODOX-M/R-IVAC) with central nervous system prophylaxis...Ampullary BL should be considered in pediatric patients with obstructive jaundice and upper gastrointestinal bleeding. Surgical biliary decompression can stabilize cholestasis and facilitate timely multi-agent chemotherapy.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • MME (Membrane Metalloendopeptidase)
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • methotrexate IV
    3d
    Case Report: From multiple myeloma to plasmablastic lymphoma - a diagnostic dilemma in unraveling a rare transformation. (PubMed, Front Oncol)
    The patient was subsequently treated with DA-EPOCH chemotherapy (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), leading to significant regression of disease on interim PET scan. This case represents the 10th reported transformation of MM to PBL and highlights the diagnostic dilemma posed by these entities. It underscores the importance of clinical context, the potential for clonal evolution (evidenced by a light-chain switch), and the efficacy of lymphoma-specific chemotherapy in this setting.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD79A (CD79a Molecule)
    |
    doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone
    3d
    DUET-UC-NK: Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=42, Recruiting, Beijing Biotech
    New P1 trial • First-in-human
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    cyclophosphamide • fludarabine IV
    3d
    Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL (clinicaltrials.gov)
    P2, N=50, Recruiting, Ou Bai, MD/PHD
    New P2 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide)
    3d
    Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide
    3d
    REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemotherapy in second line metastatic colorectal cancer carcinoma (2024-516709-22-00)
    P2/3, N=94, Recruiting, Centre Hospitalier Regional Universitaire | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • cyclophosphamide • Stivarga (regorafenib) • oxaliplatin • irinotecan • aspirin
    3d
    FLU-CART: Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy (2025-524278-40-00)
    P4, N=75, Not yet recruiting, Universitair Ziekenhuis Gent
    New P4 trial
    |
    cyclophosphamide • Yescarta (axicabtagene ciloleucel) • Kymriah (tisagenlecleucel-T) • fludarabine IV • Tecartus (brexucabtagene autoleucel) • Carvykti (ciltacabtagene autoleucel)
    3d
    MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases (clinicaltrials.gov)
    P2, N=132, Not yet recruiting, Masonic Cancer Center, University of Minnesota
    New P2 trial
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • fludarabine IV • Grafapex (treosulfan)